Epithelial ovarian tumors are responsive to steroid hormone stimulation and the ovarian stroma may have a direct role in this process. We evaluated immunohistochemical markers of sex-steroid differentiation and steroidogenesis (calretinin, inhibin, steroidogenic factor 1), steroid enzymes involved in hormone biosynthesis (CYP17, CYP19, HSD17β1, AKR1C3), and hormone receptors (estrogen receptor, progesterone receptor, and androgen receptor) in 101 epithelial ovarian tumors and in normal structures implicated in ovarian carcinogenesis (ovarian surface epithelium and cortical inclusion cysts) in an attempt to elucidate this process. We hypothesized that ovarian stroma immediately adjacent to tumors express markers of sex-steroid differentiation and steroidogenesis and steroid enzymes whereas the epithelium contains corresponding hormone receptors. As the findings in seromucinous, endometrioid, and clear cell neoplasms, tumors closely associated with endometriosis, were very similar, these were combined into a group designated 'endometriosisrelated tumors.' Significantly increased expression of markers of sex-steroid differentiation and steroidogenesis was found in stroma immediately adjacent to endometriosis-related tumors (P = 0.003) and mucinous tumors (primary and metastatic mucinous tumors were combined because of similar findings) (P o0.0001) compared with more remote ovarian stroma. In addition, sex-steroid enzymes were increased in stroma adjacent to endometriosis-related tumors (P = 0.02) and mucinous tumors (P = 0.02) compared with more distant stroma. Steroid hormone receptors showed greater expression in epithelium compared with stroma in the endometriosisrelated tumors (P = 0.0009), low-grade serous tumors (P o0.0001), and high-grade serous carcinoma (P = 0.0036). In contrast, there was greater expression in stroma compared with epithelium (Po 0.0001) in mucinous tumors, which may be due to the fact that they are not derived from müllerian epithelium. In conclusion, our findings strongly support the view that the stroma surrounding epithelial tumors in the ovary is activated to elaborate steroid hormones which may stimulate further neoplastic growth. The precise mechanisms by which this process might occur are complex and require further investigation. Modern Pathology (2017) 30, 563-576; doi:10.1038/modpathol.2016 published online 6 January 2017 The traditional view regarding the origin and pathogenesis of epithelial ovarian carcinomas is that they develop from the ovarian surface epithelium or from cortical inclusion cysts through a process of invagination of ovarian surface epithelium. As carcinomas generally resemble the epithelium in the organs from which they are derived, the müllerian phenotype of epithelial ovarian cancers has been difficult to reconcile if their proposed origin is from the ovarian surface epithelium, which
The traditional view regarding the origin and pathogenesis of epithelial ovarian carcinomas is that they develop from the ovarian surface epithelium or from cortical inclusion cysts through a process of invagination of ovarian surface epithelium. As carcinomas generally resemble the epithelium in the organs from which they are derived, the müllerian phenotype of epithelial ovarian cancers has been difficult to reconcile if their proposed origin is from the ovarian surface epithelium, which is essentially mesothelium. Accordingly, their mül-lerian phenotype has been explained by invoking metaplasia of the ovarian surface epithelium to müllerian-type epithelium which then undergoes malignant transformation. Recently, a less complex explanation for the müllerian phenotype of these tumors has been advanced by proposing that the precursor lesion of invasive high-grade serous carcinoma is an intraepithelial carcinoma in the fallopian tube, so-called serous tubal intraepithelial carcinoma that implants on the ovary. [1] [2] [3] [4] [5] [6] [7] [8] [9] It has also been suggested that some serous tumors might develop from cortical inclusion cysts lined by tubal-type epithelium derived from the fallopian tube at the time of ovulation. 1 Endometrioid and clear cell carcinomas are thought to develop from endometriosis which is generally thought to be derived from endometrial tissue by retrograde menstruation. [1] [2] [3] An obvious question is why do these tumors have a propensity to develop in the ovary rather than in the organ that is the site of the putative precursor lesion.
There is evidence that sex-steroid hormones have a role in ovarian carcinogenesis as demonstrated by studies showing that women on hormone replacement therapy have a significantly increased risk for ovarian cancer. 10 In addition, cell culture studies have shown that hormones, including estradiol, progesterone, and androgens, may modulate the growth of epithelial ovarian cancer cells by stimulating cell proliferation and telomerase expression, inducing angiogenesis, and regulating metastasis through the PI3K/AKT pathway. [11] [12] [13] [14] [15] [16] In 1964, Scully described the presence of luteinized stromal cells immediately adjacent to primary and metastatic ovarian tumors and reported oxidative-enzyme activity in these cells, referring to them as enzymatically active stromal cells. He postulated that enzymatically active stromal cells stimulated growth of implanted epithelium by local synthesis of steroid hormones. 17 With the availability of reagents that can identify enzymes involved in steroidogenesis, we undertook a morphologic and immunohistochemical analysis of the ovarian stroma from a variety of epithelial tumors, endometriotic cysts, and normal components of the ovary that have been proposed as possible precursors of ovarian cancer (ovarian surface epithelium and cortical inclusion cysts) to validate this hypothesis.
Materials and methods

Case Selection
A total of 101 ovarian tissues (neoplasms and normal tissue) and 11 normal fallopian tubes were retrieved from the pathology files of the Johns Hopkins Hospital (Baltimore, MD, USA) and Legacy Health Systems (Portland, OR, USA) from 1993 through 2014. All available slides and reports were reviewed. A total of 133 sections were evaluated from the 101 cases (one to three sections per case). These included 62 sections from malignant epithelial neoplasms (30 high-grade serous carcinomas, 6 low-grade serous carcinomas, 11 endometrioid carcinomas, 5 clear cell carcinomas, 1 mucinous carcinoma, 3 seromucinous carcinomas, and 6 metastatic carcinomas (3 colorectal and 3 low-grade appendiceal mucinous neoplasms), 33 atypical proliferative (borderline) tumors (19 serous, 6 seromucinous, and 8 mucinous, including 1 with intraepithelial carcinoma), 5 benign tumors (3 mucinous cystadenomas and 2 clear cell adenofibromas), 11 ovarian endometriosis/endometriotic cysts, 6 cortical inclusion cysts lined by tubal-type epithelium, 11 ovarian surface epithelium samples, and 5 normal ovaries. In addition, 10 sections of normal fallopian tube were evaluated.
Immunohistochemistry
The primary antibodies and conditions are shown in Table 1 . Formalin-fixed, paraffin-embedded sections were immunostained using protocols described previously. 18 The reagents used are all commercially available and listed in Table 1 and the tests were performed in accordance with the manufacturer's recommendations.
Description of the Selected Antibodies
Markers of sex-cord differentiation and steroidogenesis included calretinin, inhibin alpha, and steroidogenic factor 1 (SF-1). Markers of sex-steroid hormone receptors included estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR). Markers of enzymes involved in sex steroidogenesis included CYP19 (cytochrome P450 family 19 or aromatase), CYP17 (cytochrome P450 family 17 or 17alpha-hydroxylase), HSD17β1 (17beta-hydroxysteroid dehydrogenase type 1), and AKR1C3 (aldo-keto reductase family 1 member C3 or 17beta-hydroxysteroid dehydrogenase type 5). Table 2 summarizes the selected immunohistochemical targets and their functions, while Figure 1 illustrates the specific functions of the sex-steroid enzymes in the steroidogenesis pathway. 
CYP17
Enzyme involved in the production of progestins, estrogens and androgens, including catalyzing the cleavage of the C17-C20 bond of C21 steroids that is essential for the biosynthesis of androgens Cytochrome P450, family 19 (aromatase)
CYP19
Enzyme that catalyzes the last steps of estrogen biosynthesis, converting testosterone to estradiol 17beta-hydroxysteroid dehydrogenase type 1
HSD17β1 Enzyme that converts low activity estrone to the more potent estradiol Figure 1 Steroidogenesis. Schematic representation of the steroidogenesis pathway of steroid hormone production and some of the major enzymes involved.
Immunohistochemical Scoring
Nuclear expression of SF-1, AR, ER, and PR, cytoplasmic expression of inhibin, and nuclear and/or cytoplasmic expression of calretinin, CYP19, CYP17, HSD17β1, and AKR1C3 were considered positive when 45% of cells reacted. A semiquantitative scoring system was utilized, taking into account both the proportion of positive cells (5-25% +, 425-50% ++, 450-75% +++, 475% ++++) and the intensity of immunostaining [mild +(faint immunoreactivity at low power), moderate ++ (modest immunoreactivity at low power), or strong +++ (immunoreactivity easily appreciable at low power)]. 19 The average proportion of positive cells and the average intensity were calculated for each marker. Immunoreactivity and intensity of staining was evaluated in the epithelium, stroma immediately adjacent to the epithelium (defined as ovarian stroma closely applied to the epithelium of the tumor, endometriosis or cortical inclusion cysts), and stroma that was distant from the epithelium (defined as ovarian stroma that was ≥ 10 mm away from the epithelium). Adjacent endometriosis was not present on sections evaluated for any of the tumors such as clear cell and endometrioid carcinomas and therefore only ovarian-type (and not endometrial-type) stroma was used for the analysis. To correlate the proportion of positive cells and intensity of immunostaining, the values were converted into composite immunohistochemical scores by multiplying the individual scores of proportion of positive cells by intensity. For example, a case with + ++ proportion of positive cells (3 points) and strong + ++ intensity (3 points) of immunostaining would have an immunohistochemical composite score of 9 (3 × 3). The average composite immunohistochemical score for each marker were then calculated and the differences of the means (epithelium vs adjacent stroma and adjacent vs distant stroma within each type of ovarian lesion, ie epithelium vs adjacent stroma in high-grade serous carcinoma) were statistically analyzed using the Student t-test (two-tailed). In addition, the correlation between specific enzyme expression in the adjacent stroma and the corresponding hormone receptors in the epithelium and stroma within each type of ovarian lesion (ie, CYP17 and AKR1C3 with AR; CYP19 and HSD17β1 with ER) were evaluated using linear regression. All Pvalues o 0.05 were considered statistically significant.
Results
Morphology
Ovarian stromal cells not surrounding follicles and stromal cells at a distance from the lesional epithelium were spindled cells with scant cytoplasm. In contrast, the stromal cells immediately adjacent to the lesional epithelium had variable morphology. Those associated with endometriosis/endometriotic cysts and benign, atypical proliferative (borderline) and malignant neoplasms were composed predominantly of lutein or theca-like cells ( Figure 2 ). Luteinlike cells are polygonal cells with abundant eosinophilic or vacuolated cytoplasm and round nuclei, while theca-like cells are oval or plump spindledshaped cells that are densely cellular near the epithelium. 20 In some instances there was a mixture of the two types of cells. The differences in the expression of markers in adjacent and distant stromal cells could be a result of the stromal cell type composition or a transformation of the spindled cells into hormone producing lutein or theca-like cells. However in our study, as well as in a previous report 20 there was no difference in the localization of the antigens despite the varying stromal morphology, therefore we did not distinguish them in our analysis. Metastatic tumors and some malignant ovarian neoplasms had desmoplastic stroma composed of fibroblastic-like spindled cells with pale cytoplasm. Desmoplastic stroma was distinguished from luteinized stroma and was negative for all markers tested.
Immunohistochemical Findings
Preliminary analysis revealed some correlation between the markers in the ovarian stroma and in the epithelium depending on the specific ovarian lesions and tumors. Given these findings and based on known and reported clinicopathologic, immunohistochemical, and molecular data on the general groups of ovarian epithelial tumors and ovarian carcinogenesis which has been recently summarized, 21 we grouped the tumors and performed statistical analysis in four categories as follows: (1) endometriosis-related tumors (atypical proliferative (borderline) seromucinous tumors, [22] [23] [24] [25] [26] clear cell carcinoma, endometrioid carcinoma and seromucinous carcinoma), (2) low-grade serous tumors (atypical proliferative (borderline) serous tumors and low-grade serous carcinoma) (3) highgrade serous carcinoma, and (4) intestinal-type mucinous tumors (atypical proliferative (borderline) mucinous tumors, primary, and metastatic mucinous carcinoma). Primary and metastatic mucinous carcinomas, classified accordingly based on the criteria in the 2014 WHO Classification of Tumours of the Female Reproductive Organs, 27 
There was a statistically significant difference in the composite score for calretinin, inhibin and SF-1 together in the adjacent vs the distant stroma in endometriosis-related tumors (P = 0.0038) and Comparison of average total composite score in adjacent stroma and average total composite score in distant stroma using t-test. e Average composite score of all of the markers combined. Figure 3 Representative sections of endometriosis-related tumors with column a demonstrating an endometrioid carcinoma including a hematoxylin and eosin-stained (H&E) section. Strong nuclear immunoreactivity for progesterone receptor (PR) is seen in the malignant epithelium (similar expression of estrogen receptor (ER) and androgen receptor (AR) were also observed in this case; not illustrated). Sexsteroid enzymes CYP17 and CYP19 are observed in the stroma immediately adjacent to the epithelium. Column b shows a clear cell carcinoma including including a H&E-stained section. Nuclear immunoreactivity for steroidogenic factor 1 (SF-1) and cytoplasmic and nuclear immunoreactivity for calretinin are present in the stromal cells. Sex-steroid enzyme CYP17 is present in the stroma immediately adjacent to the epithelium.
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Steroid hormone synthesis by ovarian stroma mucinous tumors (P o 0.0001) ( Table 3 ). This was also the case when individual markers were compared. In contrast, for low-grade serous tumors and highgrade serous carcinoma, there was no statistically significant difference in the adjacent compared with the distant stroma. However, in high-grade serous carcinoma, calretinin was significantly higher in the adjacent vs the distant stroma (P = 0.0289) while SF-1 was higher in the distant vs the adjacent stroma (P = 0.0279). No differences were observed in the individual markers in low-grade serous tumors.
Markers of Sex-Steroid Enzymes (CYP17, CYP19, HSD17b1, and AKR1C3)
There was significantly increased expression of these combined markers in the adjacent compared with the distant stroma for the endometriosis-related tumors (P = 0.0203) and the mucinous tumors (P = 0.0167) ( Table 4 ). More specifically, CYP17, an enzyme involved in the biosynthesis of androgens, was significantly higher in the adjacent compared with the distant stroma in endometriosis-related tumors (P = 0.0078) and mucinous tumors (P = 0.0010), but AKR1C3, another enzyme involved in androgen biosynthesis, was not significantly increased in the adjacent compared with the distant stroma. Interestingly it was also expressed in the epithelium of the mucinous tumors. Expression of CYP19 (aromatase), which is involved in the conversion of testosterone to estradiol, and HSD17β1, an enzyme that converts low activity estrone to the more potent estradiol, was not statistically different between the adjacent and distant stroma. There was also no significant difference in the expression of these markers in the stroma associated with lowgrade serous tumors and high-grade serous carcinoma.
Markers of Sex-Steroid Hormone Receptors (Androgen Receptor, Estrogen Receptor, and Progesterone Receptor)
Expression of ER was significantly higher in the epithelium compared with the adjacent stroma of endometriosis-related tumors (P = 0.00001), lowgrade serous tumors (P o 0.0001), and high-grade serous carcinoma (P = 0.0036) (Table 5) . Similarly, there was a statistically significant increased expression of ER in the epitheium compared with the adjacent stroma of low-grade serous tumors (P = 0.0003) and high-grade serous carcinoma (P o 0.0001) and PR in the epithelium compared with the adjacent stroma of endometriosis-related tumors (P = 0.0104), whereas there was significantly decreased expression of ER (P o 0.0001) and PR (P = 0.0108) in the epithelium compared with the adjacent stroma of mucinous tumors. In contrast, AR was significantly decreased in the epithelium compared with the adjacent stroma of endometriosisrelated tumors and mucinous tumors.
Comparison of Sex-Steroid Enzyme Expression in Stroma Immediately Adjacent to Epithelium and Hormone Receptors in the Corresponding Epithelium and in the Stroma Immediately Adjacent to Epithelium
Overall, 27 cases that expressed CYP17, which is essential for the biosynthesis of androgens, also had AR available for review. In endometriosis-related tumors, greater CYP17 expression correlated with greater AR expression within the adjacent stroma in endometriosis-related tumors (r 2 = 0.8696, P = 0.0208, n = 5) and mucinous tumors (r 2 = 0.5366, P = 0.0104, n = 11). Interestingly, in high-grade serous carcinoma (r 2 = 0.6630, P = 0.0486, n = 6), a statistically significant inverse relationship was observed with greater CYP17 expression in adjacent stroma correlating with less AR expression in the epithelium, suggesting a potential interplay between the enzyme and its corresponding hormone receptor. These findings suggest that these enzymes may be producing hormones that support the stroma itself in an autocrine fashion but not necessarily with the epithelium.
A total of 44 cases with AKR1C3 expression also had corresponding AR for analysis. Interestingly, in low-grade serous tumors (r 2 = 0.5490, P = 0.0567, n = 7) there was a trend for increased AKR1C3 expression (an enzyme involved in androgen biosynthesis) in adjacent stroma with greater AR in epithelium, while in high-grade serous carcinoma, (r 2 = 0.2509, P = 0.0176, n = 22), greater AKR1C3 expression significantly correlated with greater AR expression within the adjacent stroma itself. These findings also support a potential function of the stroma of producing androgens that stimulate the stroma as well as the epithelium.
A total of 15 cases with CYP19, which is essential for the biosynthesis of estrogens, also had corresponding ER for analysis. In high-grade serous carcinoma, greater CYP19 significantly correlated with greater ER expression within the adjacent Figure 4 Representative sections of serous tumors with column a showing a high-grade serous carcinoma including a hematoxylin and eosin-stained (H&E) section. Strong nuclear immunoreactivity for estrogen receptor (ER) is seen in the malignant epithelium. Sex-steroid enzymes CYP17 and CYP19 are observed in the stroma immediately adjacent to the epithelium. Column b represents a low-grade serous carcinoma including a H&E-stained section. Strong immunoreactivity for ER is seen in the epithelium, while focal cytoplasmic and nuclear immunoreactivity for calretinin is present in the stromal cells. Sex-steroid enzyme AKR1C3 is present in the stroma immediately adjacent to the epithelium. stroma itself (r 2 = 0.7921, P = 0.0175, n = 6), again suggesting a potential autocrine function in the adjacent stroma.
No other significant correlations were observed.
Expression of Sex-Steroid Markers and Enzymes and
Expression of calretinin, inhibin and SF-1 was significantly less in the adjacent compared with the distant stroma for cortical inclusion cysts (P = 0.0479) and ovarian surface epithelium (P = 0.0002). The epithelium in cortical inclusion cysts had significantly greater hormone receptor (AR, ER, and PR) expression than the adjacent stroma (P = 0.0262) but expression of sex-steroid enzymes in the adjacent stroma was low and did not differ from that of the distant stroma. Statistically significant differences were not observed in ovarian surface epithelium with regards to these markers. There was a trend of greater expression of sexsteroid enzymes in the adjacent compared with the distant stroma in endometriosis (P = 0.0586) but Figure 5 Representative sections of mucinous tumors with column A demonstrating a mucinous carcinoma including a hematoxylin and eosin-stained (H&E) section. Immunoreactivity for steroidogenic factor 1 (SF-1) is present in the stromal cells, while strong immunoreactivity for progesterone receptor (PR) and androgen receptor (AR) is seen in the malignant epithelium. Sex-steroid enzymes CYP17 and CYP19 are observed in the stroma immediately adjacent to the epithelium. Column B shows an atypical proliferative (borderline) mucinous tumor including a H&E-stained section. Nuclear immunoreactivity for SF-1 and cytoplasmic immunoreactivity for inhibin are present in the stromal cells. Sex-steroid enzyme CYP17 is present in the stroma immediately adjacent to the epithelium. Figure 6 Representative sections of a cortical inclusion cyst with activated stroma including a hematoxylin and eosin-stained (H&E) section. Cytoplasmic immunoreactivity for inhibin is present in the stromal cells. Sex-steroid enzyme AKR1C3 is focally present in the stroma immediately adjacent to the epithelium.
there were no significant differences in sex-steroid marker and hormone receptor expression in these lesions.
The majority of both fallopian tube epithelium and adjacent stroma expressed ER, PR, AR, and AKR1C3, while in one-third of the cases adjacent stroma was immunoreactive for calretinin. The other markers were not expressed in either the epithelium or stroma. Overall, no significant findings were observed in the fallopian tubes.
Discussion
The demonstration of enzymes involved in steroidogenesis in the stroma immediately adjacent to ovarian tumors and the presence of corresponding hormone receptors in the epithelium of some of these tumors confirms previous reports 20, 28, 29 and provides compelling evidence that the epithelium of ovarian tumors activates the surrounding stroma to produce steroid hormones, and, that these hormones can potentially stimulate the growth of the tumors. In contrast to the typical ovarian stroma, but similar to the theca interna surrounding developing follicles, the ovarian stroma immediately adjacent to ovarian neoplasms is composed of lutein-like or theca-like cells which are particularly prominent in mucinous tumors, both primary and metastatic (Figure 2b) . However, the overall number of mucinous tumors in this series is small and therefore we are unable to draw firm conclusions for this tumor type. Further, given that a majority of our cases were referred cases, complete clinical information including menstrual status were not available and could not be correlated with our findings.
SF-1 is a nuclear transcription factor that is thought to regulate the gene for the alpha subunit of inhibin and plays an important role in the development of the gonads and adrenal glands, sexual differentiation, reproduction, and metabolism. [30] [31] [32] [33] In endometriosis-related and mucinous tumors, SF-1 was expressed significantly more in the adjacent compared with the distant stroma. Inhibin, a member of the transforming growth factor superfamily with growth promoting activities 34 has a paracrine action in the ovary and regulates luteinizing hormone-induced androgen production by theca cells. 35, 36 We found that inhibin was significantly increased in the stroma adjacent to mucinous tumors. Calretinin, a 29-kD calcium-binding protein structurally related to inhibin, 37 was also elevated in the stroma adjacent to endometriosis-related, mucinous tumors, and high-grade serous carcinoma.
The significantly increased expression of enzymes involved in the synthesis of sex-steroid hormones in the stroma immediately adjacent to most of the tumors, especially endometriosis-related and mucinous tumors, strongly suggests that locally produced steroid hormones may support the growth and proliferation of these neoplasms. Of the four enzymes evaluated, CYP17, an enzyme that catalyzes the C17-C20 bond side chain cleavage of C21 steroids and is therefore essential for the biosynthesis of androgens, 38 was the most significantly expressed enzyme in stroma of the various tumors, particularly in endometriosis-related and mucinous tumors. More specifically, increased CYP17 correlated with increased AR expression in the stroma itself. Curiously, increased expression of CYP17 in the stroma correlated with decreased expression of AR in the corresponding epithelium of high-grade serous carcinoma. These findings suggest an intricate interplay between the neoplasms and the ovarian stroma, including a possible negative feedback mechanism between the hormones in the stroma and the receptors in the epithelium.
In attempting to understand the possible role of locally synthesized steroid hormones and tumorigenesis, the conversion of androgens to estrogen also needs to be considered. A recent study suggests that significant amounts of estrogen are likely to be the result of peripheral aromatization of androgens 20 and although ovarian stromal cells express enzymes supporting their capacity to convert androgens to estrogens, 28, 29 it remains to be seen whether this occurs locally. In our study no correlation was observed between CYP17 in the stroma and ER in the epithelium of any of the tumors. Similarly, AKR1C3, an enzyme that catalyzes the reversible conversion of the 17-keto and 17β-hydroxy groups in androgens and estrogens, including the conversion of androstenedione to testosterone, 38, 39 was consistently immunoreactive in the ovarian stroma of many tumors in our study, but there was no significant correlation between AKR1C3 expression and AR expression in the neoplastic epithelium. Conversely, increased AKR1C3 correlated with increased AR in the adjacent stroma. This, along with the CYP17 expression, suggests that androgens, in addition to being a source of estrogens, may be important in stimulating the stroma itself, acting in an autocrine fashion. Previous studies have implicated androgens in the pathogenesis of ovarian cancer 40 and have reported that within the ovaries, the secretion rate of androgens is higher than that of estrogens. 41 In addition, animal models have indicated that testosterone stimulates the growth in vivo of ovarian surface papillomas and cystadenomas. 42 CYP19 (cytochrome P450 aromatase, an enzyme involved in the final step of estrogen synthesis, converting testosterone to estradiol 17, 38, 43 ), was expressed in several tumors, however no significant findings were observed. Likewise, a significant correlation between CYP19 and ER in the neoplastic epithelium was not seen. However, there was a correlation with greater ER in the adjacent stroma itself, specifically in high-grade serous carcinoma, again suggesting a possible autocrine function.
HSD17β1, an enzyme that converts low activity estrone to the more potent estradiol, 38 was the least frequently expressed and no significant correlation was observed with ER expression in either the epithelium or in the stroma.
Overall, our results showed that ovarian stroma, particularly the stroma immediately adjacent to epithelium, was consistently immunoreactive for inhibin, calretinin and SF-1, CYP17, and AKR1C3, less frequently for CYP19, and rarely for HSD17β1. Inhibin, calretinin and SF-1 identify hormonally active cells whereas the enzymes specifically indicate that these cells are the site of steroid hormone synthesis. The intense localization of these enzymes not only in the stroma surrounding the tumor but also within nests of tumor cells in contrast to the stroma distant from the tumors in the vast majority of ovarian neoplasms evaluated strongly suggests that there is an interaction between the tumors and the stroma. Further, steroid hormone receptors, including androgen receptor, were frequently expressed in the epithelium of the vast majority of tumors with the notable exception of mucinous tumors, therefore demonstrating their capacity to be stimulated by the hormones produced by the stroma. The absence of hormone receptors in the epithelium of mucinous tumors may be due to their not being derived from müllerian epithelium.
In endometriosis, activated ovarian stroma was also present adjacent to epithelium. Although greater composite scores for expression of markers of steroidogenesis and steroid enzymes were present in adjacent stroma in these lesions, the findings were not statistically different compared with distant stroma. The finding that hormone receptors were consistently expressed in endometriosis epithelium and adjacent stroma suggests that stroma may stimulate the epithelium in endometriosis as well.
Another interesting observation was the presence of activated ovarian stroma surrounding cortical inclusion cysts lined by tubal-type epithelium and the presence of hormone receptors in the epithelium albeit overall less than that of the ovarian tumors ( Figure 6 ). We also evaluated ovarian surface epithelium and found minimal expression of SF-1, negligible inhibin and only rare expression of only AKR1C3 in the underlying stroma, with some expression of hormone receptors in the epithelium. Despite some immunoreactivity, the expression of markers of steroidogenesis and steroid enzymes was significantly less in the adjacent stroma surrounding cortical inclusion cysts and beneath the ovarian surface epithelium compared with the distant ovarian stroma. These findings suggest that unlike the tumors, benign epithelium does not lead to activation of the stroma.
In conclusion, this study provides morphologic and immunohistochemical evidence that tumors in the ovary activate the stroma to produce steroid hormones, most often androgens, and provides one possible explanation of why tumors thought to be derived from the fallopian tube and endometrium may grow preferentially in the ovary. Additional studies are needed to confirm whether the activated ovarian stroma surrounding neoplasms produces estrogens and androgens and, if so, whether their levels are sufficient to stimulate and support tumor growth. The potential interaction of the stroma and the ovarian carcinomas is highly provocative as it may open the door for novel approaches to treatment as the activated ovarian stroma may serve as a therapeutic target for anti-androgenic drugs.
